Home > Cardiology > ESC 2021 > EMPEROR-Preserved: Light at the end of the tunnel for HFpEF patients

EMPEROR-Preserved: Light at the end of the tunnel for HFpEF patients

Presented By
Prof. Stefan Anker, Charité University Hospital, Germany
Conference
ESC 2021
Trial
EMPEROR-Preserved
EMPEROR-Preserved proved to be a landmark trial in heart failure research. It demonstrated a clinically meaningful benefit of 21% reduction in the primary composite outcome as well as positive results in secondary outcomes with empagliflozin therapy for patients with heart failure with preserved ejection fraction (HFpEF). The findings of the EMPEROR-Preserved (NCT03057951) trial were among those most eagerly awaited at this year´s ESC meeting [1]. The study aimed to assess empagliflozin as add-on to standard of care for HFpEF patients. It included 5,988 patients with HFpEF who had been hospitalised for HF within the last 12 months or were diagnosed with structural heart disease and ejection fraction over 40%. EMPEROR-Preserved was conducted as multinational trial at 622 different sites in 23 countries worldwide. After randomisation, participants with NYHA class 2–4 and eGFR ≥20 mL/minute/...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on